Analysis of the antitumor effect of cSBL for the development of new anticancer drug

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K07198
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Tohoku Medical and Pharmaceutical University
• Principal Investigator: Tatsuta Takeo 東北医科薬科大学, 薬学部, 講師 (70438563)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: リボヌクレアーゼ / アポトーシス

Outline of Final Research Achievements

An analysis of the effects of cSBL on bladder cancer demonstrated its effectiveness, with advantages in terms of cancer cell selectivity compared to other drugs. Comprehensive genetic analysis comparing cSBL-resistant cells with the parent cell line revealed that cSBL reduces the expression of ABC transporters, which are involved in cancer malignancy and resistance, and suppresses the increased expression of AKR1B10, known to contribute to resistance to doxorubicin and other drugs. Additionally, it was found that cSBL induces strong activation of c-Jun, suggesting that this activation may play an important role in the antitumor action of cSBL.

Free Research Field

生化学

Academic Significance and Societal Importance of the Research Achievements

本研究では，有効な新規治療薬が望まれている膀胱がんに対する cSBL の有効性が示された．また悪性中皮腫を用いた研究では，cSBL の抗腫瘍作用機序の解明が進んだ他，多剤耐性に関わる分子の発現を cSBL が抑制することが見出された．これは，がんの耐性化や悪性化といった現行のがん治療おける課題を，cSBL を用いることにより克服できる可能性を示すのものである．したがって，既存のがん療法に cSBL を加えることにより新しい選択肢を与える可能性があると考えられる．